Show simple item record

dc.contributor.authorDominguez, P. A.en
dc.contributor.authorDervisis, Nikolaos G.en
dc.contributor.authorCadile, C. D.en
dc.contributor.authorSarbu, L.en
dc.contributor.authorKitchell, B. E.en
dc.date.accessioned2016-11-15T20:50:46Zen
dc.date.available2016-11-15T20:50:46Zen
dc.date.issued2009-01-01en
dc.identifier.issn0891-6640en
dc.identifier.urihttp://hdl.handle.net/10919/73463en
dc.description.abstractBackground: Response and adverse reactions to combined gemcitabine (GEM) and carboplatin (CARBO) therapy in dogs with carcinomas are not documented. Hypothesis: GEM and CARBO are safe for the treatment of dogs with carcinomas. Animals: Thirty-seven dogs with histologically or cytologically confirmed carcinomas. Methods: Prospective clinical trial. Dogs were treated with GEM (2 mg/kg, 20–30-minute infusion IV) on Days 1 and 8 and 4 hours later, CARBO (10 mg/kg IV) on Day 1. The cycle was repeated on Day 22. Results: Thirty-seven dogs (29 with measurable tumor) received a median of 2 cycles (range 0.5–6) for a total of 101 cycles administered. Twelve dogs (32%) developed neutropenia (3 Grade 3, and 5 Grade 4) and 9 (24%) thrombocytopenia (2 Grade 3, and 1 Grade 4). Dogs 420 kg were twice as likely to develop thrombocytopenia (P 5 .023). Twenty-seven dogs (73%) had evidence of gastrointestinal (GI) toxicosis, but most signs were of mild to moderate severity and self-limiting. One dog died of treatment-related complications. Overall tumor response rate was 13%. One dog with metastatic prostatic carcinoma achieved a complete remission and 1 dog with intestinal adenocarcinoma and 1 with tonsillar squamous cell carcinoma achieved partial remission. Twelve dogs achieved stable disease for a median of 72 days. Conclusion and Clinical Importance: GEM and CARBO combination causes mild to moderate hematologic and GI toxicosis in dogs with carcinoma. Response rate in this study was modest, and optimization of dosing of this combination is required.en
dc.format.extent130 - 137 (8) page(s)en
dc.languageEnglishen
dc.publisherWiley-Blackwell Publishing, Incen
dc.relation.urihttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000262283900020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=930d57c9ac61a043676db62af60056c1en
dc.rightsIn Copyrighten
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en
dc.subjectVeterinary Sciencesen
dc.subjectVETERINARY SCIENCESen
dc.subjectAntimetaboliteen
dc.subjectCanineen
dc.subjectChemotherapyen
dc.subjectPlatinum agenten
dc.subjectSynergismen
dc.subjectTRANSITIONAL-CELL CARCINOMAen
dc.subjectPHASE-I TRIALen
dc.subjectLUNG-CANCERen
dc.subjectSYNERGISTIC INTERACTIONen
dc.subjectVETERINARY-MEDICINEen
dc.subjectPRIMARY METABOLITEen
dc.subjectCLINICAL-TRIALen
dc.subjectCISPLATINen
dc.subjectCHEMOTHERAPYen
dc.subjectPHARMACOKINETICSen
dc.titleCombined Gemcitabine and Carboplatin Therapy for Carcinomas in Dogsen
dc.typeArticle - Refereeden
dc.description.notesPublished (Publication status)en
dc.title.serialJOURNAL OF VETERINARY INTERNAL MEDICINEen
dc.identifier.doihttps://doi.org/10.1111/j.1939-1676.2008.0248.xen
dc.identifier.volume23en
dc.identifier.issue1en
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/Veterinary Medicineen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/CVM T&R Facultyen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/Small Animal Clinical Sciencesen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record